Page last updated: 2024-08-24

aripiprazole and levodopa

aripiprazole has been researched along with levodopa in 6 studies

Research

Studies (6)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's3 (50.00)29.6817
2010's3 (50.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Lombardo, F; Obach, RS; Waters, NJ1
Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ1
Connemann, BJ; Schönfeldt-Lecuona, C1
Bernardi, S; Edito, F; Meco, G; Purcaro, C; Stirpe, P; Valente, M; Vanacore, N1
Fujino, J; Tabushi, K; Tanaka, H; Taniguchi, N1
Arakawa, R; Ito, H; Kodaka, F; Nogami, T; Suhara, T; Suzuki, M; Takahashi, H; Takahata, K; Takano, H1

Trials

1 trial(s) available for aripiprazole and levodopa

ArticleYear
Aripiprazole in L-dopa-induced dyskinesias: a one-year open-label pilot study.
    Journal of neural transmission (Vienna, Austria : 1996), 2009, Volume: 116, Issue:7

    Topics: Adrenergic alpha-Antagonists; Aged; Aged, 80 and over; Amantadine; Antiparkinson Agents; Antipsychotic Agents; Aripiprazole; Basal Ganglia; Dopamine; Dose-Response Relationship, Drug; Drug Interactions; Dyskinesia, Drug-Induced; Female; Humans; Levodopa; Male; Mianserin; Middle Aged; Mirtazapine; Pilot Projects; Piperazines; Quinolones; Receptors, Dopamine D2; Receptors, Serotonin; Treatment Outcome

2009

Other Studies

5 other study(ies) available for aripiprazole and levodopa

ArticleYear
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
    Drug metabolism and disposition: the biological fate of chemicals, 2008, Volume: 36, Issue:7

    Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding

2008
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
    Toxicological sciences : an official journal of the Society of Toxicology, 2013, Volume: 136, Issue:1

    Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests

2013
Aripiprazole and Parkinson's disease psychosis.
    The American journal of psychiatry, 2004, Volume: 161, Issue:2

    Topics: Aged; Antipsychotic Agents; Aripiprazole; Dopamine Agonists; Dose-Response Relationship, Drug; Humans; Levodopa; Male; Parkinson Disease; Piperazines; Psychoses, Substance-Induced; Quinolones

2004
Effectiveness of aripiprazole in a patient with presumed idiopathic Parkinson's disease and chronic paranoid schizophrenia.
    Psychiatry and clinical neurosciences, 2010, Volume: 64, Issue:1

    Topics: Antiparkinson Agents; Antipsychotic Agents; Aripiprazole; Chronic Disease; Drug Interactions; Female; Humans; Levodopa; Middle Aged; Parkinson Disease; Piperazines; Psychiatric Status Rating Scales; Quinolones; Schizophrenia, Paranoid

2010
Effects of dopamine D2 receptor partial agonist antipsychotic aripiprazole on dopamine synthesis in human brain measured by PET with L-[β-11C]DOPA.
    PloS one, 2012, Volume: 7, Issue:9

    Topics: Adult; Antipsychotic Agents; Aripiprazole; Binding, Competitive; Carbon Radioisotopes; Caudate Nucleus; Dopamine; Dopamine D2 Receptor Antagonists; Humans; Levodopa; Male; Neuroimaging; Piperazines; Positron-Emission Tomography; Putamen; Quinolones; Raclopride; Radiopharmaceuticals; Receptors, Dopamine D2; Tissue Distribution; Young Adult

2012